Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...

Image Credit: Supplied Dubai: The home solutions brand Casa Milano marked Downtown Design 2024 with its largest-ever booth, a 400 square metre display, at Dubai Design District (d3). It offered an ...

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50. David Windley has given his Hold rating due to a combination ...

SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the ...

While the deal would not weigh heavily on Roche’s own production operations, “it could be a problem for other smaller players if there is a restriction in terms of how many CMOs are available ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

(RTTNews) - Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will continue to operate as a global, independent ...

EU antitrust regulators to decide on Novo Holdings' Catalent buy by Dec. 6 Novo announced $16.5 billion acquisition in February Novo Nordisk seeking to boost output of Wegovy weight-loss drug ...

Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a ...

Update 12:30pm: Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Holdings to purchase Catalent ...